 |
 |

Inflammatory Breast CarcinomaEffective Multimodal Approach
Gary V. Burton, MD;
Edwin B. Cox, MD;
George S. Leight, Jr, MD;
Leonard R. Prosnitz, MD;
James D. Iglehart, MD;
Gregg A. Olsen, MD;
Hilliard F. Seigler, MD;
Lowell L. Hart, MD
Arch Surg. 1987;122(11):1329-1332.
Abstract
Twenty-two patients with inflammatory breast carcinoma received preoperative chemotherapy consisting of weekly administration of cyclophosphamide, doxorubicin hydrochloride, fluorouracil, and vincristine sulfate for six weeks. Postoperative therapy consisted of 22 weeks of biweekly administration of these drugs. Regional radiotherapeutic consolidation followed chemotherapy. Nineteen patients completed therapy. Twelve of these patients remain disease free (median, 15 months; range, four to 32 months). Median disease-free survival for all 22 patients is 13 months or more (range, zero to 32 months). Median overall survival is 18 months or more (range, one to 33 months). This regimen compares favorably with prolonged adjuvant and maintenance chemotherapy for inflammatory breast carcinoma.
(Arch Surg 1987;122:1329-1332)
Author Affiliations
From the Departments of Medicine (Drs Burton, Cox, Olsen, and Hart), Surgery (Drs Leight, Iglehart, and Seigler), and Radiation Therapy (Dr Prosnitz), Duke University Medical Center, Durham, NC. Dr Burton is now with the Department of Medicine, Louisiana State University Medical Center, Shreveport.
Footnotes
Accepted for publication July 13, 1987.
Read before the Annual Meeting of the Society of Surgical Oncology, London, April 26, 1987.
Reprint requests to Department of Medicine, Hematology/Oncology Section, Louisiana State University Medical Center, 1501 Kings Highway, Shreveport, LA 71130 (Dr Burton).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Inflammatory Breast Cancer
Moore et al.
Arch Surg 1991;126:304-306.
ABSTRACT
|